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SUMMARY
Osteoporosis and fractures are common and invalidating consequences of chronic glucorticoid (GC) treatment. 
Reliable information regarding the epidemiology of GC induced osteoporosis (GIOP) comes exclusively from 
the placebo group of randomized clinical trials while observational studies are generally lacking data on the 
real prevalence of vertebral fractures, GC dosage and primary diagnosis. The objective of this study was to 
evaluate the prevalence and incidence of osteoporotic fractures and to identify their major determinants (pri-
mary disease, GC dosage, bone mineral density, risk factors, specific treatment for GIOP) in a large cohort of 
consecutive patients aged >21 years, on chronic treatment with GC (≥5 mg prednisone - PN - equivalent) and 
attending rheumatology centers located all over Italy. Glucocorticoid Induced OsTeoporosis TOol (GIOTTO) is 
a national multicenter cross-sectional and longitudinal observational study. 553 patients suffering from Rheu-
matoid Arthritis (RA), Polymyalgia Rheumatica (PMR) and Connective Tissue Diseases (CTDs) and in chronic 
treatment with GCs were enrolled. 
Osteoporotic BMD values (T score <-2.5) were observed in 28%, 38% and 35% of patients with CTDs, PMR 
or RA at the lumbar spine, and in 18%, 29% and 26% at the femoral neck, respectively. Before GC treat-
ment, prevalent clinical fractures were reported by 12%, 37% and 17% of patients with CTDs, PMR, or RA, 
respectively. New clinical fragility fractures during GC treatment were reported by 12%, 10% and 23% of 
CTDs, PMR and RA patients, respectively. Vertebral fractures were the prevailing type of fragility fracture. 
More than 30% of patients had recurrence of fracture. An average of 80% of patients were in supplementation 
with calcium and/or vitamin D during treatment with GCs. Respectively, 64%, 80%, and 72% of the CTDs, 
PMR and RA patients were on pharmacological treatment for GIOP, almost exclusively with bisphosphonates. 
The GIOTTO study might provide relevant contributions to clinical practice, in particular by highlighting and 
quantifying in real life the prevalence of GIOP and relative fractures, the frequency of the main risk factors, 
and the currently sub-optimal prevention. Moreover, these results emphasize the importance of the underlying 
rheumatic disease on the risk of GIOP associated fractures.
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n	 INTRODUCTION 
Glucocorticoid therapy (GCs) is a fre-quently used treatment for rheumatic 
diseases, such as Rheumatoid Arthritis 
(RA), Polymyalgia Rheumatica (PMR), 
and Connective Tissue Diseases (CTDs) 
such as Systemic Lupus Erythematosus 
(SLE) (1-3). 
In RA the use of low-dose GCs has a well-
defined effect on disease activity (4). Differ-
ent studies about early RA have demonstrat-
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lapse, without significant response to GCs 
or experiencing GC-related adverse events 
(18). GCs are extensively used also for the 
treatment of CTDs and their complications 
or flares. 
The use of GCs is associated with the oc-
currence of side effects, including hyper-
tension, diabetes mellitus, and cataract (19, 
20). One of the main complications of long-
term GCs use is an important alteration of 
bone metabolism. Bone loss associated 
with GCs generally involves trabecular and 
cortical bone, with increased bone resorp-
tion but mainly decreased bone formation 
(21). Bone loss is likely to proceed more 
rapidly and involves firstly the trabecular 
compartment because trabecular bone has 
more available surface upon which the 
cycle of resorption and formation occurs. 
Rapid bone loss is marked mostly on endo-
cortical surfaces (22). Doses of GCs >5 mg 
PN equivalent per day are associated with 
bone loss due to reduced bone formation. 
Doses of <5 mg per day may be skeletal 
sparing, but it is uncertain whether doses 
<5 mg are efficacious (23). 
Fracture risk is positively related to dai-
ly dose and increases during the first 6 
months of therapy (24). The relative risk 
of fractures for patients in GCs therapy is 
higher for forearm, hip and vertebral sites 
(24). Some confounding factors such as ac-
tivity of the disease, age of the patient, sex, 
baseline BMD, previous fracture history, 
may influence the rate of bone loss (25). 
The effects of GCs on fracture risk as well 
as being dose-related, also depend on the 
duration of the therapy (26).
Reliable information regarding the epi-
demiology of GC induced osteoporosis 
(GIOP) comes exclusively from the pla-
cebo group of randomized clinical trials 
while observational studies are generally 
lacking data on the real prevalence of ver-
tebral fractures, GC dosage and primary 
diagnosis.
The main objective of this multicenter 
study was to evaluate, with a transversal 
and longitudinal approach, in real life, 
the prevalence and incidence of osteopo-
rotic fractures and to identify their major 
determinants in a sample of patients with 
ed that the treatment with disease-modifying 
anti-rheumatic drugs (DMARDs) in associ-
ation with GCs may induce high and persis-
tent remission rates (5). 
This disease-modifying effect of GCs is 
supported by different studies (5-12). In 
addition, the results also showed that GCs 
have an action in retarding the progression 
of erosive joint damage in early RA (prior to 
any joint damage) and a control of disease 
activity (5-12). The CAMERA II study, in 
which patients with RA were treated with 
10 mg/day of prednisone, has demonstrated 
that the co-treatment with GCs has a role 
in the treat-to-target and tight control strat-
egy (13). Many reviews concluded that a 
low dose of GCs (<7.5 mg/day) can repre-
sent a bridging-therapy while waiting for 
DMARDs to begin to have effect (8, 13). 
This conclusion was recommended by EU-
LAR in 2010 and then in a 2014 update (14-
16). The 2012 ACR recommendations up-
date concerned only the use of conventional 
DMARDs and biological therapies, while it 
did not recommend the use of GCs (17). In 
RA the combination therapy with GCs (at 
a stable low dose of 7.5 mg/day) and tradi-
tional DMARDs frequently leads to a sup-
pression of inflammation, and allows a last-
ing clinical remission (5).
GCs represent the gold standard treatment 
in PMR, reducing symptoms and suppress-
ing inflammation within a few weeks. GCs 
act as inhibitors of the circadian release of 
pro-inflammatory cytokines (such as IL-6), 
reducing the duration of morning stiffness 
(2). Although a universal regimen of daily 
doses of GCs in PMR is not accepted, the 
EULAR/ACR 2015 recommendations for 
the management of PMR suggest an initial 
GCs administration dose within a range of 
12.5-25 mg prednisone (PN), and then of 
10 mg for 4-8 weeks before being tapered 
by 1 mg every 4-8 weeks (18). In addition, 
the experts panel discourages conditionally 
the use of initial doses of ≤7.5 mg/day or 
>30 mg/day. At the same time, the panel 
recommends considering the early intro-
duction of methotrexate (MTX) in addition 
to GCs, particularly in patients at a high 
risk of relapse. MTX may also be consid-
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different rheumatic diseases in chronic 
treatment with GCs. Secondary objectives 
were to quantify the prevalence of the ma-
jor risk factors for osteoporotic fracture: 
age, underlying disease, sex, bone min-
eral density (BMD), dietary intake of cal-
cium, specific anti-osteoporotic therapy, 
estimate of vitamin D, physical activity, 
smoking, alcohol, family history, comor-
bidity and falls.
n	 MATERIALS AND METHODS
This is a national multicenter cross-sec-
tional and longitudinal observational study 
(The Glucocorticoid Induced OsTeopo-
rosis TOol, GIOTTO Study). 553 patients 
suffering from RA, PMR and CTDs and in 
chronic treatment with GCs were enrolled 
in the Italian rheumatologic centers of Ve-
rona, Vercelli, Mantova, Pavia, Modena, 
Bologna, Florence, Pisa, Siena, Ancona, 
Rome, Naples, Foggia, Lecce, Reggio Cal-
abria, Catania, and Cagliari.
The study was purely observational so no 
additional treatments or tests other than 
those normally applied to these patients, 
were provided or requested.
Each center enrolled patients arriving con-
secutively in their outpatients clinics and 
within the following inclusion criteria:
– for the cross-sectional phase: women or 
men age >21 years and receiving GCs 
for at least one year at a dose of at least 
5 mg/day of PN or equivalent
– for the longitudinal phase:  patients 
in therapy  with GCs (at least 5 mg/
day)  for  less than  three months and in 
which a therapy with GCs was expected 
for at least one year at a dosage of at 
least 5 mg/day of PN or equivalent.
All subjects with at least one of the fol-
lowing characteristics were excluded from 
the study: a diagnosis of metabolic bone 
diseases or other forms of secondary os-
teoporosis (uncontrolled hyperthyroidism, 
M. Cushing, malabsorption syndrome, pri-
mary hyperparathyroidism), severe renal 
insufficiency (serum creatinine >2 mg/dl), 
severe liver failure. Patients on aromatase 
inhibitors, androgen deprivation therapy 
and heparin were also excluded.
Additional diagnostic tests (instrumental 
or biochemical) deemed appropriate by the 
investigator for the clinical practice were 
provided. The prevalence and incidence of 
fractures were referred to so-called clinical 
fractures (but also to any vertebral frac-
tures detected incidentally by radiographic 
investigation of the spine).
The data collection cards (CRF) included 
information about medical history, clinical, 
diagnostic and therapeutic data, in particu-
lar: demographics; physiological and path-
ological history; assessment of the state 
of the rheumatic disease and concomitant 
Health Assessment Questionnaire; previ-
ous drug therapy; previous and ongoing 
GC therapy; specific medical history for 
osteoporosis (date of first diagnosis; date 
of first fragility fracture; previous verte-
bral and non-vertebral fractures before 
the start of GC treatment; new fractures 
on GC treatment; recurrence of vertebral 
fractures; risk factors for osteoporosis or 
fracture); outcome of laboratory examina-
tions; previous/ongoing drug therapy for 
osteoporosis; assessment of the quality of 
life (EQ-5D); simplified questionnaire on 
calcium and vitamin D intake and physical 
activity.
The study was approved by the Ethics 
Committee and by the local coordina-
tor. All patients provided written informed 
consent.
Descriptive statistics analysis included: 
sample size, mean, standard deviation, 
median and range for continuous vari-
Table I - Features of Patients depending on the Rheumatic Disease (Mean ± SD).
Rheumatic diseases No. F/M Age (yrs) BMI (kg/m2) Cumulative dose (g) Length of therapy (mo)
AR 183 157/26 64±13* 25±5 20.3±22.9 108±91
CTDs 249 206/43 57±16* 25±4 23.9±42.9 79±84*
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ables; absolute and relative frequency dis-
tributions for categorical variables.
n	 RESULTS
A total of 553 patients with RA, CTDs 
(mainly SLE =93%) or PMR in chronic 
treatment with GCs were recruited. Table I 
shows the main clinical features of the pa-
tients depending on the disease. 
The prevalence of the main risk factors for 
osteoporosis and fracture, according to the 
disease that requested GCs chronic thera-
py, is shown in Table II.
The prevalence of osteoporosis according 
to DXA (T-score <-2.5) was at the spine in 
28%, 38% and 35% of patients with CTDs, 
PMR or RA;  at the femur, on the other 
hand,  it was  respectively 18%, 29% and 
26% (Figure 1).
A prevalence of previous clinical fractures 
was found in 12%, 37% and 17% of pa-
tients suffering respectively from CTDs, 
PMR, or RA before any treatment with GC 
(Figure 2A).
During treatment with GC new clinical fra-
gility fractures were reported in 12%, 10% 
and 23% of patients suffering respectively 
from CTDs, PMR and RA (Figure 2B).
The prevailing type of fragility fracture was 
vertebral, in particular multiple vertebral 
fractures in patients suffering from PMR 
(Figure 3A).
More  than  30%  of patients had recur-
rence  of vertebral fracture. A  second  re-
lapse of a vertebral fracture was  found in 
Table II - Prevalence of risk factors for osteoporosis or fracture, according to 
the Rheumatic Disease.
Risk factors RA CTDs PMR
Family history of fractures 15% 23% 13%
Alcohol habits 20% 19% 34%
Smoking habits (currently/previous) 19%/23% 19%/17% 9%/26%
Falls during last 6 months 20% 15% 19%
No physical activity 42% 42% 39%
Sunlight exposure <1/week 37% 35% 18%
No seaside holiday 66% 63% 60%
Low calcium intake 30% 23% 34%
Comorbidities 78% 76% 98%
VAS-EQ-5D<50%* 23% 18% 20%
*Visual analogue scale for recording European Quality of Life-5 Dimensions.
Figure 2 - A) Prevalence of patients with fractures pre-GC treatment, according to the Rheu-
matic Diseases; B) Prevalence of patients with new clinical fragility fractures in the different 
Rheumatic Diseases during GC treatment.
Figure 1 - Prevalence of osteoporosis at spine or femoral neck de-
pending on the Rheumatic Disease.
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20%  of patients with CTDs  and 10% of 
those with RA (Figure 3B).
In addition, considering only calcium and/
or vitamin  D,  an average of  80%  of  pa-
tients  were  in supplementation during 
treatment with GCs; only few of them were 
already on treatment before the beginning 
of the GCs treatment (Figure 4A). 
64% of patients with CTDs, 80% of pa-
tients with PMR and 72% of patients with 
RA, were treated  with specific drugs  for 
the prevention or treatment of GIOP, and in 
particular with anti-resorptive drugs (alen-
dronate or risedronate) (Figure 4B).
The patients included  in the prospective 
longitudinal phase of the study, which 
met the inclusion and  exclusion crite-
ria, were 83. Their assessment did not show 
any significant results in addition to those 
shown  by  the retrospective longitudinal 
analysis of 553 cases.
n	 DISCUSSION  
AND CONCLUSIONS
The main aim of this multicenter study was 
to evaluate the prevalence and the inci-
dence of osteoporotic fractures in a cohort 
of patients with different rheumatic diseas-
es and in therapy with chronic GCs. 
In this study we have observed that in RA 
patients in treatment with GCs, the preva-
lence of osteoporosis according to DXA, 
in terms of T-score <-2.5, was of 35% at 
the spine, while it was 26% at the femur. In 
previous studies the frequency of general-
ized osteoporosis in the global population 
of patients with RA, with or without GC 
treatment, ranged from 12.3 to 38.9% in the 
lumbar spine and from 6.3 to 36.3% in the 
hip (27-29). The frequencies of osteoporo-
sis in the subgroups of RA patients accord-
ing to current prednisolone use were 26.6% 
and 24.7% at the spine and femoral neck, 
respectively (27). The KORONA database 
(including 77.7% GCs users) showed that 
the frequency of osteoporosis was 46.8% 
(30), a higher percentage in comparison to 
some other studies, which reported a preva-
lence of 22-24 %, but with a lower preva-
lence of GC use (31, 32). In a large Italian 
multicenter cross-sectional study that in-
Figure 3 - A) Distribution of different types of fractures, in the different 
diseases, during GC treatment; B) Prevalence of RA or CTDs patients 
with recurrence of fractures during GC treatment.
Figure 4 - A) Prevalence of patients with calcium and/or vitamin D 
supplementation, before or during GC treatment, according to the 
Rheumatic Disease; B) Prevalence of patients on prevention or treat-
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cluded 925 female RA patients, the authors 
reported that the frequency of osteoporosis 
in the whole sample was 28.8% at the lum-
bar spine and 36.2% at the femoral neck. 
GC use was associated with significantly 
lower lumbar and femoral BMD (28). 
In our study the prevalence of osteoporosis 
in patients with CTDs (mainly SLE) was 
of 28% at the spine and 18% at the hip. Re-
cently, Carli et al observed that more than 
50% of SLE patients chronically treated 
with GCs had a reduced BMD and 28% 
had osteoporosis (33). In previous stud-
ies the prevalence of osteoporosis in GC 
treated patients with SLE ranged from 1.4 
to 68% (34, 35). Two recent studies have 
demonstrated that bone loss occurs mainly 
in SLE patients treated with at least 7.5 mg/
day prednisone, while treatment with lower 
doses of prednisone is not associated with 
bone loss (36, 37).
The frequency of osteoporosis in patients 
with PMR in previous studies ranges be-
tween 14.9 and 85%. In our experience, 
in these elderly patients osteoporosis was 
generally found in 38% at the spine and 
29% at the hip. 
Risk of fracture in patients who received 
long-term GC is about 33-50%, depend-
ing on daily and cumulative dose (38). This 
variability can be explained by the use of 
different age groups in the study popula-
tions, the menopausal status of the partici-
pants, and the use of GCs. In addition, we 
observed that the prevalence of previous 
clinical fractures before any GCs treat-
ment was 12% in patients with CTDs, 37% 
in patients with PMR and 17% in patients 
with RA. This finding may be determined 
by the role of an underlying inflammation, 
with the exception of PMR where other 
factors such as an older age or a higher 
prevalence of comorbidities could play a 
role. In the general population, even small 
elevations of C reactive protein within the 
normal range increase non-traumatic frac-
ture risk (39). In some studies, the levels 
of inflammatory markers and cytokines 
predicted bone loss and were predictive 
for fractures (40, 41). There is a strong 
biological rationale for these observations. 
Osteoclastogenesis is under the control of 
RANK-ligand, which is mainly produced 
by osteocytes in normal bone remodelling, 
but also by lymphocytes and fibroblasts 
in other conditions such as inflammation 
(42). Osteoclastogenesis can be enhanced 
by many cytokines: interleukin (IL) IL-6, 
IL-23, Tumor necrosis factor α (TNF-α). 
TNF-α transgenic mice are models of os-
teoporosis with dramatic decrease in bone 
mass and deterioration of bone microar-
chitecture. In addition, an over-expression 
of a Wnt inhibitor, sclerostin, has been 
observed in these models, with a conse-
quence of inflammation-related decrease in 
bone formation (43). Moreover, alterations 
in other Wnt inhibitors, such as DKK1, 
might be involved in inflammation-related 
bone loss (44). These findings show that in-
flammation has a deleterious effect on bone 
remodelling, inducing increased resorption 
and decreased formation, before any effect 
of GCs themselves. Paradoxically, GCs 
might play a dual role: they induce bone 
loss and on the other hand they suppress 
systemic inflammation with a subsequent 
beneficial effect on bone mass (3). 
Autoimmunity, too, might have a role in 
bone remodelling. For example, in RA the 
adaptive immune system produces anti-
bodies against rheumatoid factor (RF) and/
or against cyclic citrullinated peptides (an-
tibodies to citrullinated protein antigens 
or ACPA). The plasma levels of ACPA are 
an index of disease activity and joint dam-
age (45). A recent study has shown that 
ACPA can stimulate osteoclast differen-
tiation, and that in ACPA-positive patients 
with RA there is more frequent evidence 
of bone loss and thinning of cortical thick-
ness than in APCA-negative patients with 
RA (46-48). Recently, a significant correla-
tion has been observed between RA related 
osteoporosis and risk of erosions (49, 50). 
The incidence of new fragility fractures 
during GCs treatment in our cohort of pa-
tients was 12% in CTDs, 10% in PMR, and 
23% in RA. The prevailing type of fracture 
was vertebral, in particular multiple verte-
bral fractures, especially in patients with 
PMR. It is known that the risk of fractures 
is doubled in patients with GCs, and the 
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In a study comparing 244,235 oral GCs 
users versus controls, the relative risk of 
hip fracture was 1.6, and the relative risk 
of vertebral fracture was 2.6. Many stud-
ies have confirmed these results (24, 51, 
52). The global prevalence of fractures 
in patients receiving long-term GCs has 
been reported as 30-50%. In 551 patients 
receiving long-term GCs, the prevalence 
of vertebral fractures was 37%, with 14% 
of patients having 2 or more asymptom-
atic vertebral fractures; 48% of patients 
aged ≥70 years and 30% of those aged 
<60 years had at least one vertebral frac-
ture (53). The increase in fracture risk is 
immediate, as early as 3 months after the 
initiation of therapy and it reverses sharply 
after discontinuation of GCs (24). This can 
be related to the added effects of GCs on 
bone remodeling previously unleashed by 
the inflammation itself, and the dramatic 
effect on bone strength through induced 
apoptosis of osteocytes. Data also suggest 
a rapid increase in the rate of falls after the 
start of oral GCs (24). In epidemiological 
studies, the increased risk of fractures is 
observed even at low doses of prednisone, 
that is, 2.5-5 mg per day. The appropriate 
care of patients receiving such low doses 
is not well defined. There is a dose-depen-
dent increase in fracture incidence. Inter-
estingly, the fracture risk is related to the 
current daily dose, more than to the cumu-
lative dose (54): this may be related to the 
difficulty of an accurate calculation of this 
cumulative dose.
Secondary objectives of this study were 
to quantify the prevalence of the princi-
pal risk factors for osteoporotic fractures. 
The prevalence of comorbidities was very 
high, especially in PMR. No physical ac-
tivity was found in about 40% of the pa-
tients, independently of the rheumatic dis-
ease, and the prevalence of falls was high, 
in particular in RA and PMR (about 20%). 
Immobilization due to pain from inflamed 
joints and impairment of physical activity 
are known key factors related to low BMD 
and are common in patients suffering from 
rheumatic diseases (55). The risk of falls 
may be higher in RA patients because of 
lower limb joint disease and muscle weak-
ness (due to GCs therapy and disuse) (56). 
An increased fall risk in 89% of the RA 
patients was found (57). Potential interven-
tions to reduce falls in this kind of patient 
include control of disease activity, rehabili-
tation or exercise therapy, balance training, 
occupational therapy, home assessment 
and treatment of vitamin D deficiency. A 
study by Bearne et al. suggested that a brief 
rehabilitation can improve the quadriceps 
sensorimotor function (58). 
In addition, in our patients we found high 
prevalence of low sunlight exposure and 
low calcium intake. Vitamin D deficiency 
is common in patients with rheumatic dis-
ease, and associated with disease activ-
ity (59-61). We also evaluated the regular 
intake of calcium and vitamin D supple-
ments before and during therapy with GCs. 
We observed that only a few patients were 
on supplementation before starting GCs 
therapy, while about 80% of patients were 
taking calcium or vitamin D supplements 
during GCs therapy, as recommended (62).
In our study, prevention or treatment of 
GIOP with specific drugs for osteoporo-
sis appear sub-optimal, and generally re-
stricted to anti-resorptive approach with 
bisphosphonates (63), despite it is well 
known that inhibition of bone formation 
and increased apoptosis of osteocytes play 
a consistent and crucial role in the patho-
genesis, while changes in bone resorption 
during GCs use are variable. Although it 
has been shown that bisphosphonates re-
duce vertebral fractures during the first 2 
years of GC treatment, there are no data on 
long-term use, and, it is known that they 
reduce bone turnover, including bone for-
mation, which is already downwards reg-
ulated by GCs. Effectively, the use of the 
anabolic agent teriparatide was found more 
successful in reducing vertebral fractures 
than alendronate (64). 
This study has a number of limitations, 
mainly linked to its cross-sectional design 
and patient selection bias. Moreover, in or-
der to define severe renal insufficiency, a 
glomerular filtration rate would have been 
better than serum creatinine cut off, given 
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In conclusion, the GIOTTO study might 
provide relevant contributions to clinical 
practice, in particular by highlighting and 
quantifying in real life the prevalence of 
GIOP and relative fractures, the frequen-
cy  of the main risk factors, and the cur-
rently sub-optimal prevention. Moreover, 
these results emphasize the importance of 
the underlying rheumatic disease on the 
risk of GIOP associated fractures.
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